



BioRegeneration Company Profile



Business Address:

Head Office: Unit 13 first floor. No. 202 Nasibi Street, Banihashem Ave... Tehran-Iran Tel: +98 (021) 22 518674

ZIP Code: 1665816762 Email: info@taskinbr.com

Website: www.taskinbr.com



Hospital Address:

South side Imam Hossein Square, Taskin Medical Complex Rafsanjan-Iran Tel:+98 (034) 34292648 ZIP Code: 7713977943 Website: www.taskinhospital.com



Taskin Bioregeneration Co.


Innovating Affordable Cell and Gene Therapies for Global Health



Company Overview

Taskin Bioregeneration Co. is a pioneering biotechnology company based in Iran, specializing in developing and commercializing advanced cell and gene therapies. Our mission is to provide transformative, life-saving treatments for patients with serious conditions such as cancer, autoimmune diseases, and inflammatory disorders. We focus on making these innovative therapies accessible and affordable, particularly in underserved regions such as the Middle East.

Built on a strong foundation in research and development (R&D) and partnerships with global experts, Taskin Bioregeneration continues to push the boundaries of medical science. Our flagship product, DestroCell, is a stromal cell-based therapy approved for Graft-versus-Host Disease (GvHD), exemplifying our commitment to delivering patient-centered solutions for inflammatory diseases. We are dedicated to regenerating health, improving outcomes, and restoring hope to patients with limited treatment options.





Our Mission and Vision









Mission

Taskin Bioregeneration is committed to revolutionizing healthcare by developing innovative cell and gene therapies that address unmet medical needs. Our mission is to make these treatments accessible, particularly in underserved and developing regions, ensuring that our therapies are affordable, safe, and effective.

Vision

Our vision is to lead the future of cell and gene therapy by creating transformative treatments that regenerate health and enhance patient well-being. We aim to be at the forefront of biotechnology, ensuring equitable access to therapies, particularly in low-income regions.





Research and Development Focus

Taskin Bioregeneration's R&D is central to our ability to transform patient care. We focus on four key areas of biotechnology:



Immunotherapy:

We are developing cost-effective CAR T-cell therapies to fight cancers such as multiple myeloma, making this life-saving treatment accessible to patients in underserved regions.



Gene Therapy:

Our team is developing therapies that target and correct genetic disorders, offering hope for conditions previously considered untreatable.



Stem Cell Therapy:

Building on DestroCell's success, we are researching additional uses for decidua stromal cells (DSCs), including in autoimmune diseases like premature ovarian failure and inflammatory conditions like ARDS and lupus.



Regenerative Medicine:

We leverage stem cells and gene editing to repair or replace damaged tissues and organs, accelerating recovery and improving outcomes for patients with degenerative diseases like arthritis, heart disease, and neurological disorders.





Our Product Pipeline

Our product pipeline reflects our commitment to turning research into real-world treatments that save lives. We focus on three core areas: oncology, autoimmune diseases, and regenerative medicine. Key products include:



DestroCell (Approved): A DSC-based therapy approved for GvHD, showing potential in other inflammatory and autoimmune diseases like ARDS and lupus. Clinical trials are underway to explore broader applications.



CAR T-Cell Therapy for Multiple Myeloma: We are developing an affordable CAR T-cell therapy for multiple myeloma, with clinical trials planned in the Middle East.



Stem Cell Therapy for Premature Ovarian Failure (Phase III Clinical Trial): This therapy uses placenta-derived stromal cells to restore ovarian function and improve fertility. Promising results are emerging from a trial involving 60 patients.




Future Projects: We are exploring gene and cell therapies for cancers, autoimmune diseases, and degenerative conditions, with a focus on CRISPR gene-editing technologies for future therapeutic development.



DesRep for Diabetic Foot Treatment (Phase III Clinical Trial):

DesRep is a groundbreaking treatment combining placenta-derived stromal cells and hydrogel to address chronic wounds and diabetic foot ulcers. Currently in Phase III clinical trials, DesRep has shown promising results in promoting wound healing and reducing complications in patients with diabetic foot ulcers. This study is being conducted in collaboration with Tehran University of Medical Sciences and other leading institutions.

Product	Indication	Pipeline	Approval
	476	Discovery Phase I/II Phase	I/III Market Authorization
TasDes01	GvHD	Graft Versus Host Diseases	
TasDes02	ARDS	Acute respiratory distress syndrome	
TasDes03	SLE	Systemic lupus erythematosus	
TasDes04	HF	Heart Failure	
TasWou01	DF	Diabetic Foot	
TasCar01	MM	Multiple Myeloma	
TasTilO1	ВС	Breast Cancer	






(2) TASKIN





Corporate Social Responsibility

At Taskin Bioregeneration, we believe that healthcare innovation must go hand in hand with social responsibility, sustainability, and ethical research. Our CSR initiatives include:



- Sustainability Initiatives: We implement green practices in our facilities, conserving resources and reducing waste to minimize our environmental footprint.
- Community Engagement: We support local communities through educational programs, internships, and partnerships with academic institutions to nurture future biotechnology leaders.
- Patient Advocacy: We collaborate with patient advocacy groups to ensure that patients' voices are heard and that our therapies improve both health outcomes and quality of life.











Collaboration is vital to Taskin Bioregeneration's strategy for accelerating the development and commercialization of therapies. Our partnerships include:

- International CDMO Partnerships: We work with contract development and manufacturing organizations (CDMOs), particularly in China, to ensure GMP-compliant vector production for our CAR T-cell programs.
- Academic Collaborations: We collaborate with universities such as Tehran University of Medical Sciences and the Royan Institute to strengthen our research and clinical trials.
- Industry Alliances: Taskin Bioregeneration engages with regulatory bodies and industry leaders to stay at the cutting edge of biotechnology, ensuring compliance with global standards like PIC/S, FDA, and Iranian regulatory requirements.



■ Empowering Local Communities

Taskin Bioregeneration is committed to fostering local community growth by investing in education, training, and job creation. We aim to build local expertise in biotechnology for long-term, sustainable development. Key initiatives include:



Training Programs: We offer internships and hands-on training for students and young professionals in biotechnology.



Job Creation: Our investment in local R&D infrastructure has created numerous high-tech jobs, contributing to the growth of the regional healthcare sector.



Educational Collaborations: We support research and development through partnerships with universities, helping build a pipeline of talented researchers and professionals.



Community Health Initiatives: Taskin Bioregeneration works with healthcare providers and patient advocacy groups to ensure that underserved communities have access to advanced therapies.





Looking to the Future

At Taskin Bioregeneration, we are dedicated to pushing the boundaries of cell and gene therapy. Our vision is to create a future where healthcare is equitable, and every patient, regardless of location or income, has access to life-saving therapies. We welcome collaborations with global partners to bring these transformative therapies to patients worldwide.





generation

